OGOliver Gruber

Oliver Gruber

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Oliver Gruber has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Family load impacts orbitofrontal volume in first-episode schizophrenia

    by Berend Malchow, Alkomiet Hasan, Kristina Meyer, Thomas Schneider-Axmann, Katrin E. Radenbach, Oliver Gruber, Wolfgang Reith, Andrew M. McIntosh, Andrea Schmitt, Peter Falkai, et al.


  • Von der Psychopathophysiologie zur Biomarker-basierten Klassifikation und stratifizierten Therapie schizophrener Störungen

    by O. Gruber

    Dieser Artikel gibt eine Übersicht über die Rolle der funktionellen Bildgebung des Gehirns für 1. das Verständnis der Symptome der Schizophrenie und der ihnen zugrundeliegenden Pathophysiologie, 2. die Erforschung der pathogenetisch relevanten genetischen und Umweltfaktoren und 3. aktuelle und zukünftige Entwicklungen einer Biomarker-basierten Klassifikation und individualisierten Therapie schizophrener Störungen. Die Bildgebung endophänotypischer Hirnfunktionsstörungen und das Genomic Imaging sind vielversprechende wissenschaftliche Ansätze, die die Entwicklung funktioneller Hirnbildgebungsmarker für klinisch relevante pathophysiologische Prozesse vorantreiben. Solche Bildgebungsbiomarker werden eine präzisere Differenzialdiagnose zwischen pathophysiologisch und pathogenetisch distinkten Subtypen schizophrener Störungen ermöglichen und eine wichtige Rolle für die Vorhersage des individuellen Ansprechens auf spezifische Therapien und somit für eine individualisierte Therapieauswahl spielen. This article gives an overview of the role of functional neuroimaging for 1. a better understanding of the phenotypic symptoms and their underlying pathophysiology, 2. research into the genetic and environmental factors involved in the pathogenesis, and 3. current and future developments towards a biomarker-based classification and tailored therapy of schizophrenic disorders. In particular, neuroimaging of endophenotypic brain dysfunctions and imaging genetics are promising research approaches as endophenotypes may guide the development of functional neuroimaging biomarkers for clinically relevant pathophysiological processes. These biomarkers may permit a more precise differential diagnosis of pathophysiological and pathogenetic subtypes of the heterogeneous diagnostic category of schizophrenic disorders. Furthermore, they may allow us to predict individual treatment responses to specific therapies and to personalise treatment selection.


  • Open Access

    Magnetic Resonance Imaging in Studying Schizophrenia, Negative Symptoms, and the Glutamate System

    by Oliver Gruber, Antonella Chadha Santuccione, Helmut Aach

    Schizophrenia is characterized by positive, negative and cognitive symptoms. While positive symptoms occur periodically during psychotic exacerbations, negative and cognitive symptoms often emerge before the first psychotic episode and persist with low functional outcome and poor prognosis. This review article outlines the importance of modern functional magnetic resonance imaging (fMRI) techniques for developing a stratified therapy of schizophrenic disorders. Functional neuroimaging evidence on the neural correlates of positive and particularly negative symptoms and cognitive deficits in schizophrenic disorders is briefly reviewed. Acute dysregulation of dopaminergic neurotransmission is crucially involved in the occurrence of psychotic symptoms. However, increasing evidence also implicates glutamatergic pathomechanisms, in particular N-methyl-D-aspartate (NMDA) receptor dysfunction in the pathogenesis of schizophrenia and in the appearance of negative symptoms and cognitive dysfunctions. In line with this notion, several gene variants affecting the NMDA receptor’s pathway have been reported to increase susceptibility for schizophrenia, and have been investigated using the imaging genetics approach. In recent years, several attempts have been made to develop medications modulating the glutamatergic pathway with modest evidences for efficacy. The most successful approaches were those that aimed at influencing this pathway using compounds that enhance NMDA receptor function. The selective glycine reuptake inhibitor Bitopertin has been shown to improve NMDA receptor hypofunction by increasing glycine concentrations in the synaptic cleft. Further research is required to test whether pharmacological agents with effects on the glutamatergic system can help to improve the treatment of negative symptoms in schizophrenic disorders.


  • Poster #M32 IMAGING ENDOPHENOTYPIC BIOMARKERS FOR SCHIZOPHRENIC AND AFFECTIVE PSYCHOSES IN KEY NEURAL CIRCUITS

    by Oliver Gruber, Henning Vieker, Sarah Trost, Anna Fanelli, Kathrin Jakob, David Zilles

  • Development of Schizoaffective Psychosis in the Course of a Long-Term Occupation as Spiritual Healer: Coincidence or Causality?

    by Julia Sadzio, Henning Vieker, Oliver Gruber, David Zilles

    Psychotic reactions in the context of meditation and esoteric practices have been described in the psychiatric literature. In most cases, these psychotic conditions are transient and do not lead to functional impairment. The authors present the case of a 46-year-old woman who had worked as a spiritual healer for several years and, in the course of this occupation, increasingly developed a highly specific configuration of psychotic symptoms (all of which could be convincingly traced back to the formerly used spiritual techniques) along with depressive symptoms and severe functional impairment. The differential diagnosis was initially complicated by the relative conformity of the patient's psychotic symptoms with her occupational practices and the absence of other, more typical, symptoms of schizophrenia. Only a thorough anamnesis with another spiritual healer and precise identification of psychopathology helped to disentangle the merely uncommon from the pathologic features of this case. Possible mechanisms of psychotogenesis are discussed in light of the literature and the specific features of the presented case. Although a single case report cannot prove a causal link between spiritual healing and development of psychosis, the patient's specific psychopathology, with preeminently disturbed self-experience, and its consistency with the patient's spiritual practices suggest at least a contributory role in this case.


  • Psychiatry in Europe

    by Oliver Gruber

  • Schizophrenia

    by Peter Falkai, Oliver Gruber, Andrea Schmitt

    Schizophrenia is a chronic neurocognitive brain disorder with unknown pathophysiology. There is evidence for an interaction between risk genes and environmental factors playing a role during early as well as late neurodevelopment leading to symptoms in early adulthood. Deficits in hippocampus-related declarative memory and decreased hippocampal volumes at the stage of first episode and during the course of the disease are key findings. Stereological postmortem studies of the hippocampus in schizophrenia revealed no alterations of neuronal cell numbers but decreased numbers of oligodendrocytes in the posterior part and a lack of astrogliosis, suggesting that schizophrenia is not a classical neurodegenerative disorder. Decreased myelination and synaptic genes support the hypothesis of impaired connectivity of the hippocampus. Dysconnectivity of the hippocampus in schizophrenia may also be related to disturbances in neurogenesis, since a reduced number of proliferating stem cells has been detected in the dentate gyrus of schizophrenia patients. Effects of several risk genes of schizophrenia like D-amino acid oxidase, neuregulin-1, dysbindin, and disrupted-in schizophrenia-1 have been demonstrated in hippocampal tissue or magnetic resonance imaging (MRI) studies. In addition, genome-wide association studies revealed new genes with widely unknown function like ZNF804 or the transcription factor TCF4. Postmortem and animal studies may elucidate the link between these risk factors and behavioural consequences such as deficits of cognition and sensorimotor gating, which are related to hippocampal function. It has, however, to be kept in mind that chronic antipsychotic treatment may have influenced results from postmortem and MRI studies.


  • Open Access

    The DTNBP1 (dysbindin-1) gene variant rs2619522 is associated with variation of hippocampal and prefrontal grey matter volumes in humans

    by S. Trost, B. Platz, J. Usher, H. Scherk, T. Wobrock, S. Ekawardhani, J. Meyer, W. Reith, P. Falkai, O. Gruber

    DTNBP1 is one of the most established susceptibility genes for schizophrenia, and hippocampal volume reduction is one of the major neuropathological findings in this severe disorder. Consistent with these findings, the encoded protein dysbindin-1 has been shown to be diminished in glutamatergic hippocampal neurons in schizophrenic patients. The aim of this study was to investigate the effects of two single nucleotide polymorphisms of DTNBP1 on grey matter volumes in human subjects using voxel-based morphometry. Seventy-two subjects were included and genotyped with respect to two single nucleotide polymorphisms of DTNBP1 (rs2619522 and rs1018381). All participants underwent structural magnetic resonance imaging (MRI). MRI data were preprocessed and statistically analysed using standard procedures as implemented in SPM5 (Statistical Parametric Mapping), in particular the voxel-based morphometry (VBM) toolbox. We found significant effects of the DTNBP1 SNP rs2619522 bilaterally in the hippocampus as well as in the anterior middle frontal gyrus and the intraparietal cortex. Carriers of the G allele showed significantly higher grey matter volumes in these brain regions than T/T homozygotes. Compatible with previous findings on a role of dysbindin in hippocampal functions as well as in major psychoses, the present study provides first direct in vivo evidence that the DTNBP1 SNP rs2619522 is associated with variation of grey matter volumes bilaterally in the hippocampus.


  • Hirnbildgebungsmarker

    by Dr. O. Gruber


  • Differential working memory performance as support for the Kraepelinian dichotomy between schizophrenia and bipolar disorder? An experimental neuropsychological study using circuit-specific working memory tasks

    by David Zilles, Raphael Jung, Eva Gruber, Peter Falkai, Oliver Gruber

    Objectives. The traditional clinical dichotomy of schizophrenia and bipolar disorder has been challenged by recent findings of an at least in part common genetic basis. The investigation of neurocognitive functions like working memory may thereby contribute to elucidate common versus distinct pathophysiological processes of the major psychoses. To date direct comparisons of working memory functioning in schizophrenia and bipolar disorder have been rare and moreover have revealed inconsistent findings. In this study we aimed to further clarify the diagnostic specificity of working memory deficits in schizophrenia and bipolar disorder. Methods. Fifty patients with schizophrenia, 23 patients with bipolar disorder and 53 healthy controls were tested with regard to specific dysfunctions of verbal and visuospatial working memory components using a set of well-characterized, brain circuit-specific paradigms with established brain-behaviour relationships. Results. Patients with schizophrenia showed marked deficits across different working memory domains while bipolar patients performed intermediate with no significant differences compared to the control group. Working memory performance of patients with schizophrenia and bipolar disorder significantly differed in only one particular task requiring articulatory rehearsal of verbal information. Conclusions. While these results do not provide unequivocal support for the Kraepelinian dichotomy, they are consistent with recent findings suggesting the existence of a specific subgroup of schizophrenia patients phenotypically characterized by selective deficits of the articulatory rehearsal mechanism of verbal working memory.